A Phase 3 Randomized, Double-Blind, Decentralized Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in the Treatment of Patients With COL3A1-Positive Vascular Ehlers-Danlos Syndrome
Latest Information Update: 11 Jun 2024
At a glance
- Drugs Celiprolol (Primary)
- Indications Ehlers-Danlos syndrome
- Focus Registrational; Therapeutic Use
- Acronyms DiSCOVER
- Sponsors Acer Therapeutics
- 03 Jun 2024 Planned End Date changed from 30 Nov 2025 to 1 Apr 2029.
- 03 Jun 2024 Planned primary completion date changed from 30 Oct 2025 to 1 Mar 2029.
- 29 Apr 2024 According to a Zevra Therapeutics media release, the company has recently restarted the recruitment in this study.